Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability.
Cells incorporate isoprenoid products derived from mevalonate (MVA) into several unique proteins. The aim of this study was to delineate the effects of blocking MVA synthesis on the covalent isoprenylation of these proteins in murine erythroleukemia cells. Inhibition of protein synthesis with cycloheximide prevented the incorporation of [3H]MVA into proteins, suggesting that isoprenylation normally occurs immediately after synthesis of the polypeptides. However, incubation of cells with lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, for as little as 1 h prior to addition of cycloheximide rendered the isoprenylation step insensitive to cycloheximide. Lovastatin had no apparent effect on the stability of the isoprenylated proteins, but the development of cycloheximide insensitivity during the lovastatin preincubation was dependent on synthesis of new protein during that period. Addition of 50-200 microM MVA to the culture medium eliminated the effects of preincubation with lovastatin. Preincubation of cells with 25-hydroxycholesterol, which suppresses the synthesis and enhances the degradation of HMG-CoA reductase but is not a competitive enzyme inhibitor, did not induce cycloheximide-insensitivity of the isoprenylation reaction. The results suggest that blocking MVA synthesis with lovastatin causes a rapid depletion of isoprenoid groups available for protein modification. Consequently, there is an accumulation of non-isoprenylated substrate proteins. Shifts in the ratio of modified vs. unmodified proteins in response to MVA availability may have implications for the changes in cell morphology, cell proliferation and HMG-CoA reductase gene expression that occur when cells are subjected to MVA deprivation.
Repko
E M
EM
Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania 17822.
Maltese
W A
WA
D000818:Animals; D002460:Cell Line; D002784:Cholesterol / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D004286:Dolichols / Q000378:metabolism*; D007700:Kinetics; D007930:Leucine / Q000378:metabolism; D008148:Lovastatin / Q000494:pharmacology; D008798:Mevalonic Acid / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D014316:Tritium; D014451:Ubiquinone / Q000378:metabolism
D004286:Dolichols; D014316:Tritium; D014451:Ubiquinone; D002784:Cholesterol; D003513:Cycloheximide; D008148:Lovastatin; D007930:Leucine; D008798:Mevalonic Acid